LH (Luteinizing Hormone)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- LH combined with FSH and testosterone instantly localizes where a hormonal problem originates in men. A man with low testosterone has either a testicular problem (primary hypogonadism: LH elevated, FSH elevated, testes unresponsive) or a pituitary/hypothalamic problem (secondary hypogonadism: LH low or inappropriately normal, FSH low, insufficient signal). This distinction matters enormously — a man with secondary hypogonadism may respond well to clomiphene (which blocks estrogen's negative feedback, increasing LH and driving endogenous testosterone production), while a man with primary hypogonadism will not respond to this approach.
- LH is required for endogenous testosterone production, which is why testosterone replacement therapy suppresses LH and FSH to near-zero. When exogenous testosterone is administered, testosterone levels rise and exert strong negative feedback on the hypothalamus and pituitary, suppressing GnRH, LH, and FSH. The testes receive no LH signal and stop producing testosterone and, critically, sperm. This is why TRT causes testicular atrophy and azoospermia during treatment. Men on TRT who wish to preserve fertility typically add hCG (human chorionic gonadotropin, which mimics LH at the testicular level) to maintain intratesticular testosterone and spermatogenesis.
- The LH:FSH ratio is a key diagnostic marker for PCOS. In women with polycystic ovary syndrome, LH is often chronically elevated while FSH remains normal or low, producing a characteristic LH:FSH ratio above 2:1. This reflects the disrupted GnRH pulsatility in PCOS — faster pulse frequency preferentially increases LH over FSH. While an elevated LH:FSH ratio is not present in all women with PCOS (and is therefore not a required diagnostic criterion), it is a clinically useful supporting finding when the clinical picture is otherwise consistent.
- The mid-cycle LH surge is the direct trigger of ovulation and the basis of ovulation predictor kits. Consumer ovulation predictor kits measure urinary LH — when the surge is detected, ovulation typically occurs 24–36 hours later, marking the optimal fertility window. For longevity monitoring purposes, detecting an LH surge in a mid-cycle sample confirms ovulation has occurred that cycle — relevant context when tracking reproductive hormonal health in the perimenopausal transition.
- Rising LH in perimenopause is a sign of the HPG axis compensating for declining ovarian responsiveness, just like FSH. As ovarian follicles become less responsive to gonadotropin stimulation with age, both LH and FSH rise in an attempt to drive ovarian activity. LH rises somewhat later and less dramatically than FSH in perimenopause, but the combined pattern of elevated LH and FSH with variable estradiol is the hormonal signature of the menopausal transition. In postmenopausal women, both LH and FSH remain chronically elevated.
The HPG Axis Command Hierarchy
Understanding LH requires placing it in the hypothalamic-pituitary-gonadal (HPG) axis — the three-tier hormonal command system that regulates sex hormone production in both sexes.
At the top: the hypothalamus, which releases GnRH (gonadotropin-releasing hormone) in pulses. The frequency and amplitude of these pulses determines which gonadotropin is preferentially released from the pituitary — slower pulses favor FSH, faster pulses favor LH.
In the middle: the pituitary, which translates GnRH signals into FSH and LH output. These two gonadotropins carry the signal to the gonads.
At the bottom: the gonads (ovaries or testes), which respond to FSH and LH to produce hormones and gametes. The sex hormones produced (estrogen, progesterone, testosterone, inhibin B) feed back to the hypothalamus and pituitary to modulate further GnRH and gonadotropin release.
LH is the final pituitary signal to the gonads for steroidogenesis — the production of sex hormones. In the testes, LH drives Leydig cells to produce testosterone. In the ovary, LH drives the LH surge that triggers ovulation and then stimulates corpus luteum progesterone production. A disruption anywhere in this axis — hypothalamus, pituitary, or gonad — can produce low sex hormones, and LH is the critical measurement that tells you where in the axis the disruption lies.
Primary vs. Secondary Hypogonadism: The Diagnostic Pivot
In clinical endocrinology, the distinction between primary and secondary hypogonadism is fundamental — and it is only reliably made by measuring LH and FSH alongside testosterone (or estrogen).
Primary hypogonadism: The gonads are failing. The pituitary is producing adequate or excess LH and FSH (high gonadotropins) trying to drive hormone production, but the gonads cannot respond. In men: high LH + high FSH + low testosterone. In women: high LH + high FSH + low estrogen. Causes include Klinefelter syndrome, prior chemotherapy or radiation, orchitis, primary ovarian insufficiency, Turner syndrome. Treatment requires replacing the missing hormone exogenously.
Secondary hypogonadism: The pituitary or hypothalamus is not sending adequate signal. LH and FSH are low or inappropriately normal despite low sex hormones. In men: low or normal LH + low FSH + low testosterone. In women: low LH + low FSH + absent menstrual cycles. Causes include prolactinoma, hypothalamic amenorrhea, hypopituitarism, exogenous testosterone or estrogen use, hypothyroidism, severe illness. Treatment aims at restoring the signaling cascade. 1
| Population / Phase | Standard Range | Longevity Optimal |
|---|---|---|
| Men (baseline) | 1.7–8.6 mIU/mL | 3–7 mIU/mL |
| Women — follicular phase | 2–15 mIU/mL | 3–10 mIU/mL |
| Women — mid-cycle surge | 22–105 mIU/mL | Physiologic — confirms ovulation |
| Men on TRT | Typically near 0 | Expected suppression by exogenous T |
| Postmenopausal women | 16–64 mIU/mL | Expected chronic elevation |
| Range Type | Value (mIU/mL) | Notes |
|---|---|---|
| Standard Clinical Range | Women — follicular phase: 2–15 mIU/mL · Women — mid-cycle surge: 22–105 mIU/mL · Women — luteal phase: 0.6–19 mIU/mL · Women — postmenopausal: 16–64 mIU/mL · Men: 1.7–8.6 mIU/mL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Men: 3–7 mIU/mL · Women (follicular phase): 3–10 mIU/mL |
Associated with reduced all-cause mortality and extended healthspan.
LH interpretation is highly context-dependent and requires knowing menstrual cycle phase in premenopausal women. The mid-cycle LH surge is a normal and expected pattern — LH values above 22 mIU/mL at mid-cycle are physiologically appropriate. In men, LH in the upper portion of the normal range alongside normal testosterone is not necessarily concerning — some variation in pulsatile LH secretion is normal. LH above the upper reference limit in a man with low testosterone is the most clinically important pattern, confirming primary testicular failure. LH that is inappropriately normal or low in the setting of low testosterone points to secondary hypogonadism requiring pituitary evaluation (prolactin, TSH, MRI if indicated).
|
Already have your results? See what your LH (Luteinizing Hormone) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What's the clinical difference between measuring LH alone versus LH + FSH together?
LH alone provides some information but is substantially more interpretable when paired with FSH. Together, LH and FSH describe the full gonadotropin output from the pituitary and allow assessment of the FSH:LH ratio, which has diagnostic significance (elevated in primary ovarian insufficiency, elevated LH relative to FSH in PCOS). In men, both should be measured alongside testosterone — a man with low testosterone, high LH, and high FSH has a clearly different picture (primary hypogonadism) from a man with low testosterone, low LH, and low FSH (secondary hypogonadism). Measuring LH or FSH in isolation forces a narrower interpretation than the two together. They are almost always ordered simultaneously in clinical practice and should be treated as a pair.
What is clomiphene (Clomid) and how does it use LH biology for testosterone optimization?
Clomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks estrogen's negative feedback on the hypothalamus and pituitary. By blocking this feedback, clomiphene allows GnRH pulses to increase, which drives up both LH and FSH, which in turn stimulates testicular testosterone and sperm production. In men with secondary hypogonadism (low testosterone due to inadequate LH signaling, not testicular failure), clomiphene can often restore testosterone to normal while preserving fertility — an alternative to exogenous testosterone replacement. It is generally not effective in primary hypogonadism (high LH with low testosterone) because the testes are already receiving maximal LH stimulation and cannot produce more testosterone. Monitoring LH response is the key way to assess whether clomiphene therapy is working — LH should rise, and testosterone should follow.
Can stress affect LH levels?
Yes — psychological and physical stress suppresses LH through multiple mechanisms. Cortisol directly inhibits GnRH pulsatility at the hypothalamic level, reducing the frequency and amplitude of LH pulses. Elevated cortisol also appears to reduce pituitary sensitivity to GnRH. This is the mechanism behind the stress-induced menstrual cycle disruption and hypothalamic amenorrhea seen in athletes, individuals with eating disorders, and people under extreme psychological stress — the hypothalamic GnRH generator slows, LH pulses become irregular or absent, and estrogen production falls. In men, chronic stress produces lower LH pulse amplitude and suppressed testosterone. This stress-LH-testosterone connection is one mechanistic reason why chronic stress produces hypogonadal symptoms in both sexes.
What is the LH surge and when during the cycle does it occur?
The LH surge is the dramatic, transient rise in LH that triggers ovulation — typically the largest hormone swing in the normal menstrual cycle. It is triggered by a positive feedback mechanism: as the dominant follicle matures and estrogen rises above a threshold (~200 pg/mL for at least 50 hours), this triggers a switch from the usual negative feedback to a positive feedback response in the hypothalamus and pituitary, producing a 5–10× surge in LH over 24–36 hours. The mature follicle ruptures approximately 24–36 hours after the LH surge onset, releasing the egg. The timing varies by individual and cycle: in a 28-day cycle it typically occurs around day 13–15, but ovulation can range widely. Ovulation predictor kits detect the LH surge in urine, which lags the serum surge by a few hours. A serum LH drawn at mid-cycle will show the elevated surge value; a value drawn outside the surge window will show the lower follicular or luteal phase level.